

Additional file 2 Synergistic drug effects of ABT-263 and A-1210477 in the SiHa and CaSki cervical cancer cell lines

SiHa				CaSki			
ABT-263 (μM)		CI	Drug combination interactions	ABT-263 (μM)		CI	Drug combination interactions
0.25		ND		0.25		0.67	Synergism
0.5		ND		0.5		0.44	Synergism
1	A-1210477	1.09	Nearly additive	1	A-1210477	0.33	Synergism
2	(4 μM)	0.55	Synergism	2	(4 μM)	0.34	Synergism
4		0.27	Strong synergism	4		0.43	Synergism
8		0.33	Synergism	8		0.57	Synergism
16		0.52	Synergism	16		0.67	Synergism
32		1.03	Nearly additive	32		1.25	Moderate synergism
A-1210477 (μM)		CI	Drug combination interactions	A-1210477 (μM)		CI	Drug combination interactions
0.25		ND		0.25		1.29	Moderate antagonism
0.5		ND		0.5		1.50	Antagonism
1	ABT-263	ND		1	ABT-263	0.67	Synergism
2	(4 μM)	0.95	Nearly additive	2	(2 μM)	0.49	Synergism
4		0.35	Synergism	4		0.39	Synergism
8		0.19	Strong synergism	8		0.31	Synergism
16		0.18	Strong synergism	16		0.32	Synergism
32		0.20	Strong synergism	32		0.75	Moderate synergism

Cells were treated with increasing concentrations of ABT-263 or A-1210477 in the presence or absence of ABT-263 or A-1210477 in the indicated concentration. Combination index values were calculated using the CompuSyn 1.0 software. CI indicates combination index; CI < 1 indicates synergism, CI = 1 indicates additivity, and CI > 1 indicates antagonism and ND = Not determined CI values could not be determined for some combination concentrations as these concentrations were too low to cause an effect on cell proliferation.